(Total Views: 235)
Posted On: 06/08/2017 11:55:03 AM
Post# of 72446
Brilacidin as a franchise: what about the rest of the colon and small intestine. Comment on formulations
Dr. B -- half of IBD is Crohn's disease which can happen throughout GI tract. Can get drug into GI tract without much systemic absorption. Pill technology has gotten quite impressive. Can target certain areas of GI tract. Would not be reinventing the wheel to do that. Some big pharmas have the technology available but don't have the right drug candidate. This sets us up toward partnership.
We need anchored results, will hear more in July in Boston. We are talking with formulation people to get this kind of stuff done. requires investment so cautious about when to pull trigger. Actively working toward it now.
OM -- We won't be shy about results. We're thrilled about active response vs. placebo was unexpected. We should finish trial this year, getting good active recruitment.
Dr. B -- half of IBD is Crohn's disease which can happen throughout GI tract. Can get drug into GI tract without much systemic absorption. Pill technology has gotten quite impressive. Can target certain areas of GI tract. Would not be reinventing the wheel to do that. Some big pharmas have the technology available but don't have the right drug candidate. This sets us up toward partnership.
We need anchored results, will hear more in July in Boston. We are talking with formulation people to get this kind of stuff done. requires investment so cautious about when to pull trigger. Actively working toward it now.
OM -- We won't be shy about results. We're thrilled about active response vs. placebo was unexpected. We should finish trial this year, getting good active recruitment.
(2)
(0)
